GlassScriptPhysician profile
Vikyath Prakash
NPI 1255665402
$33,853.29
in general payments reported to CMS, 2019-2025
26 companies · $7,683 in 2025
The $7,683 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $292 · 2021: $9,753 · 2022: $7,017 · 2023: $7,715 · 2024: $822 · 2025: $7,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,000 · Consulting Fee: $3,686 · Travel and Lodging: $2,914 · Food and Beverage: $2,568 · Education: $51.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,000.00 |
| Consulting Fee | $3,685.50 |
| Travel and Lodging | $2,914.45 |
| Food and Beverage | $2,568.09 |
| Education | $51.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $15,717.05 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $7,428.34 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $5,531.50 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $2,165.40 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $578.54 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $479.25 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $441.95 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $396.97 | 2019-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $177.96 | 2023-2025 | |
| Glaxosmithkline, LLC. | $174.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Amgen INC. | $124.35 | 2024-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $84.62 | 2023-2025 | Velphoro, Velphoro, Korsuva |
| Ani Pharmaceuticals, INC. | $65.79 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $64.18 | 2021-2025 | Vafseo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $51.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.56 | 2024 | |
| Opko Pharmaceuticals, LLC | $35.89 | 2024-2025 | Rayaldee |
| Daiichi Sankyo INC. | $34.21 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $23.69 | 2025 | Acthar |
| Novo Nordisk INC | $18.42 | 2024 | Rybelsus, Ozempic |
| Apellis Pharmaceuticals, INC. | $16.95 | 2025 | Empaveli |
| Cormedix INC. | $16.31 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.27 | 2022 | |
| Ardelyx, INC. | $14.18 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikyath Prakash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.